	US 12,071,632 B2
	Chimeric vectors
Shirin Munir, Potomac, MD (US); Linda G. Brock, Wyckoff, NJ (US); Ursula J. Buchholz, Silver Spring, MD (US); and Peter L. Collins, Silver Spring, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Appl. No. 17/049,916
Filed by The United States of America,as represented by the Secretary,Department of Health and Human Services, Bethesda, MD (US)
PCT Filed Apr. 23, 2019, PCT No. PCT/US2019/028771 § 371(c)(1), (2) Date Oct. 22, 2020, PCT Pub. No. WO2019/209859, PCT Pub. Date Oct. 31, 2019.
Claims priority of provisional application 62/661,320, filed on Apr. 23, 2019.
Prior Publication US 2021/0189425 A1, Jun. 24, 2021
Int. Cl. C12N 15/86 (2006.01); A61K 39/155 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)

CPC C12N 15/86 (2013.01) [A61K 39/155 (2013.01); A61P 31/14 (2018.01); A61K 2039/5256 (2013.01); A61K 2039/543 (2013.01); C12N 2760/18534 (2013.01); C12N 2760/18544 (2013.01); C12N 2760/18551 (2013.01)]

19 Claims

1. A live, chimeric murine pneumonia virus (MPV) vector which allows a cell to express at least one protein from at least one human pathogen, wherein the at least one human pathogen is a virus.